Despite internal modeling indicating lecanemab offers a ‘societal value’ of around $37,600 per year, the company has decided on a list price of around $26,500 annually to moderate the impact on Medicare and patients.
Eisai Co., Ltd. is carefully framing its decision to price its newly-approved Alzheimer’s treatment Leqembi (lecanemab-irmb) at $26,500 a year as one that prioritizes heath care system (mainly Medicare) sustainability and patient affordability.
Lecanemab received an accelerated approval from the US Food and Drug Administration on 6 January
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
